MARKET

RAPP

RAPP

Rapport Therapeutics Inc
NASDAQ
27.28
+0.19
+0.70%
After Hours: 27.28 0 0.00% 16:49 02/09 EST
OPEN
26.70
PREV CLOSE
27.09
HIGH
27.31
LOW
25.78
VOLUME
187.06K
TURNOVER
--
52 WEEK HIGH
42.27
52 WEEK LOW
6.43
MARKET CAP
1.30B
P/E (TTM)
-10.0505
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RAPP last week (0202-0206)?
Weekly Report · 19h ago
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
TipRanks · 4d ago
This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 02/02 16:04
Rapport Therapeutics Price Target Announced at $43.00/Share by Wells Fargo
Dow Jones · 02/02 14:57
RAPPORT THERAPEUTICS, INC. <RAPP.O>: WELLS FARGO INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $43
Reuters · 02/02 12:35
Rapport Therapeutics initiated with an Overweight at Wells Fargo
TipRanks · 02/02 11:00
Weekly Report: what happened at RAPP last week (0126-0130)?
Weekly Report · 02/02 09:51
Weekly Report: what happened at RAPP last week (0119-0123)?
Weekly Report · 01/26 09:51
More
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

Webull offers Rapport Therapeutics Inc stock information, including NASDAQ: RAPP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RAPP stock methods without spending real money on the virtual paper trading platform.